Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1 Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial

Journal:
The Lancet Neurology
Published:
DOI:
10.1016/s1474-4422(25)00426-0
Affiliations:
24
Authors:
44
Go to article
Institutions Authors Share
University of Antioquia (UdeA), Colombia
16.000000
16.000000
 0.36
Banner Alzheimer's Institute, United States of America (USA)
7.333333
 0.17
Genentech, Inc., United States of America (USA)
7.000000
 0.16
Brigham and Women's Hospital (BWH), United States of America (USA)
4.000000
 0.09
F. Hoffmann-La Roche Ltd., Switzerland
2.000000
 0.05
Banner Sun Health Research Institute, United States of America (USA)
1.333333
 0.03
Marly Clinic, Colombia
1.000000
 0.02
University of Southern California (USC), United States of America (USA)
1.000000
 0.02
University of California, San Diego (UC San Diego), United States of America (USA)
1.000000
 0.02
Hospital Pablo Tobón Uribe, Colombia
1.000000
 0.02
ESE Hospital San Juan de Dios de Yarumal, Colombia
0.500000
 0.01
Massachusetts General Hospital (MGH), United States of America (USA)
0.500000
 0.01
Sahlgrenska Academy, GU, Sweden
0.333333
 0.01
Fundacion Cardiomet Cequin, Colombia
0.333333
 0.01
Universidad del Quindío, Colombia
0.333333
 0.01
ESE Hospital Departamental Universitario del Quindío San Juan de Dios, Colombia
0.333333
 0.01
Interested in Neurosciences?